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hepatocellular carcinomaTo the Editor:
Dr. Hasegawa and the Japanese Liver Cancer Study
Group compared the outcome of surgical resection
with those of percutaneous ablation therapies using
the prospectively collected data on patients with a sin-
gle hepatocellular carcinoma (HCC) nodule or no more
than three nodules each measuring less than 3 cm in
diameter who underwent either partial hepatectomy
(n = 2857), radiofrequency ablation (RFA) (n = 3022),
or percutaneous ethanol injection (n = 1306) between
2000 and 2003. [1]. In their clinically valuable study,
it is estimated that more than 95% of patients in each
group will be alive at 2 years after initial therapy, while
the estimated 2-year time-to-recurrence rate in patients
who underwent partial hepatectomy (35.5%) is signiﬁ-
cantly lower than that in patients with RFA (55.4%)
or with percutaneous ethanol injection (73.3%). In a
Cox proportional hazard model in which 9 patient-re-
lated or tumor-related factors and types of therapy
were entered, surgical resection is an independent neg-
ative predictor for recurrence. The authors conclude
that surgical resection may oﬀer some advantages over
percutaneous ablation therapies for patients with pri-
mary HCC if the number of HCC nodules is 3 or less
and the maximum diameter of each nodule is less than
3 cm.
Although several years have passed since the last en-
try to the study, the median follow-up period was 10.4
months and a quarter of patients enrolled in the study
were followed up only over a period of 4.8 months.
First, I would like to ask the authors how many and
why patients were lost to follow-up, and whether the
rates of censored patients were similar among the three
groups. Child–Pugh score, serum albumin levels, and
indocyanine green retention at 15 min were signiﬁ-
cantly better in the resection group than in ablation
therapy groups. The number of tumors, also, was smal-
ler in the former group than in the latter groups. These
ﬁndings suggest that the treatment of choice was
dependent on functional hepatic reserve and tumor sta-
tus. These factors that were entered into a Cox propor-
tional hazard model are likely to be correlated to each
other and associated with a speciﬁc type of treatment
modalities. Second, I would like to ask the authors
whether step-wise multiple logistic regression analysis
is more appropriate than a Cox proportional hazard
model to elucidate the factors independently contribut-
ing to tumor recurrence in such situations. When com-
pared with previous reports showing that local
recurrence rates after RFA of HCC vary from 2% to
36% [2], the recurrence rate of 55.4% at 2 years after
RFA seems exceptionally high. I am concerned that
true local recurrence, newly developed HCC nodules
in the liver remnant, and extrahepatic recurrence are
all included in the analysis of tumor recurrence. Third,
I would like to ask the authors how local or distant
recurrence was deﬁned and whether surgical resection
as an initial therapy was associated with the reduction
in local recurrence rates. According to a recent work
comparing the outcomes of repeat hepatectomy with
those of salvage RFA in patients with recurrent HCC
after partial hepatectomy, among intrahepatic recur-
rences approximately 90% of recurrent tumors devel-
oped at a new area within the liver [3]. HCC
accompanying cirrhosis is an organ disease, and the
ﬁrst nodule treated is usually only a prelude to others
[4]. Therefore, incidence of appearance of new lesions
in cirrhotic liver appears not to be an adequate
measure to evaluate the eﬃcacy of each therapeutic
modality for HCC. Apart from orthotropic liver trans-
plantation that should be reserved for selective patients
with end-stage liver disease, when allowed by the hepa-
tic functional reserve and tumor status, partial hepatec-
tomy has been considered as the ﬁrst-line treatment for
both primary and recurrent HCC. However, with the
advances in operator skills and equipment used for
RFA such as expandable or open-perfused electrodes
and computer-assisted generator, it appears that RFA
has become an equally eﬀective alternative to surgical
resection for early HCC. In a recent Italian cohort
study, complete local responses to RFA were sustained
during the median follow-up period of 31 months in
212 of 218 patients with a single HCC nodule 2.0 cm
or less in diameter who received 1 or 2 sessions of
RFA [5]. Hepatic resection, especially anatomical resec-
tion, is seemingly the more suitable option for obtain-
ing the complete tumor ablation including a layer of
tissue surrounding it, whereas RFA is likely to have
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and requiring shorter duration of hospital stay. Finally,
I would like to ask the authors whether subgroup anal-
ysis according to the size and number of tumors would
be helpful to clarify the role of surgical resection and
RFA in the treatment of HCC in their large patients.
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To the Editor:
We thank Dr. Fujita for his comments on our paper
[1] describing a retrospective comparison of the clinical
eﬀects between surgical resection and percutaneous
ablation, including radiofrequency ablation (RFA), for
hepatocellular carcinoma (HCC). Four major points
were raised in his letter.
First, Dr. Fujita mentions the problem of the short
follow-up period. We agree that this is one of the limita-
tions of our study, as discussed in the paper [1]. We
think that the main reason for the short follow-up peri-
od is the long time needed to collect, collate, and analyze
the clinical data obtained from a Japanese nationwide
survey, because of the large volume of the data. On
the other hand, the drop-out rate would have little inﬂu-
ence on the follow-up period, because the drop-out rates
in the three groups were similar and not signiﬁcant. We
have no information on the reasons for the dropouts.
Second, Dr. Fujita proposed the use of the step-wise
multiple logistic regression analysis, instead of a Cox’s
proportional hazard model. According to the statistician
in our group (Yutaka Matsuyama), a Cox’s propor-
tional hazard model is more appropriate to analyze such
time-to-event data as those presented in our study. Dr.
Fujita has also indicated that the recurrence rate after
RFA was too high as compared to the ‘‘the local recur-
rence rates” reported previously. However, we deter-[4] Nakashima O, Kojiro M. Recurrence of hepatocellular carci-
noma: multicentric occurrence or intrahepatic metastasis? A
viewpoint in terms of pathology. J Hepatobiliary Pancreat Surg
2001;8:404–409.
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mined the ‘‘overall recurrence rates” (and not the
‘‘local recurrence rates”) [1], which mainly represent
the frequencies of intrahepatic metastasis and second
primary carcinogenesis. Extrahepatic recurrence is also
included in the overall recurrence rate, although it was
noted in a small proportion of the patients. Thus, the
overall recurrence rate of 55.4% at 2 years after RFA
would be rather compatible with the previously reported
rates, that is, the 2-year cumulative recurrence rate of
43.4% [2] and the 2-year cumulative event-free survival
rate of 37.4% [3], which suggest that the 2-year overall
recurrence rate was about 62.6%.
Third, Dr. Fujita raised a question on the deﬁnition
of local and distant recurrence, and about the eﬀects
of surgery on local recurrence. However, we cannot an-
swer this question, because we do not have any data to
determine the local recurrence rate. It is impossible to
discuss the type of recurrence after surgery and RFA
using the data available to us from this study.
Dr. Fujita expressed his personal opinion following
his third question. He said, ‘‘Therefore, incidence of
appearance of new lesions in cirrhotic liver appears
not to be an adequate measure to evaluate the eﬃcacy
of each therapeutic modality for HCC”. We agree that
the overall survival is the true endpoint to evaluate the
eﬀects of a treatment modality for a malignant disease,
as has been advocated [4]; however, in HCC, the recur-
